Regulus Therapeutics Inc.
RGLSHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $10.0M | $6.8M |
| Operating income | −$50.0M | −$31.1M | −$28.2M | −$27.8M | −$14.2M | −$16.8M |
| Net income | −$46.4M | −$30.0M | −$28.3M | −$27.8M | −$15.7M | −$3.3M |
| Total assets | $84.2M | $30.8M | $46.7M | $68.5M | $37.6M | $42.1M |
| Total liabilities | $7.8M | $9.6M | $13.4M | $13.5M | $11.6M | $22.1M |
| Equity | $76.4M | $21.2M | $33.3M | $55.0M | $26.0M | $20.0M |
| EPS (diluted) | $-0.82 | $-1.58 | $1.86 | $3.24 | $-0.45 | — |
| Shares out. | 65.5M | 16.8M | 146.0M | 72.5M | 21.0M | 10.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- −60.7%
- Return on assets
- −55.1%
- Return on capital (ROCE)
- −65.3%
- Liabilities / assets
- 9.2%
- Debt / equity
- 0.10×
- Book value / share
- $1.17
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -9.51distress
- Accruals / assets
- −5.6%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Deep Track Capital, LpPassive (13G)Aug 14, 2025
- Point72 Asset Management, L.P.Passive (13G)Aug 14, 2025
- Vivo Opportunity Fund Holdings, L.P.Passive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Jun 13, 2025 | 1.8M | 1.4 | -15.8% |
| May 30, 2025 | 2.1M | 2.3 | +9.3% |
| May 15, 2025 | 1.9M | 1.1 | -29.5% |
| Apr 30, 2025 | 2.7M | 1.0 | +28.4% |
| Apr 15, 2025 | 2.1M | 2.2 | -20.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJun 25, 2025
- Results of operationsMay 8, 2025
- Entered a material agreement · Director / officer change · Other material eventApr 30, 2025
- Regulation FD disclosure · Other material eventMar 27, 2025
- Results of operationsMar 13, 2025
- Entered a material agreementMar 4, 2025
- Results of operationsNov 7, 2024
- Entered a material agreementOct 24, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.